Product Description
An orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fruquintinib#:~:text=An%20orally%20available%2C%20small%20molecule,anti%2Dangiogenic%20and%20antineoplastic%20activities.)
Mechanisms of Action: VEGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Colorectal Cancer|Oncology Solid Tumor UnspecifiedPriority Review - Endometrial Cancer *
Approval Status: Approved
Approved Countries: China
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: Hutchison Medipharma
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, China, Czech Republic, Estonia, France, Germany, Hungary, Italy, Japan, Korea, Poland, Spain, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 18
Highest Development Phases
Phase 3: Colorectal Cancer|Endometrial Cancer|Renal Cell Carcinoma
Phase 2: Acute Respiratory Distress Syndrome|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Small Cell Lung Cancer|Triple Negative Breast Cancer
Phase 1: Kidney Diseases|Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024-013-00CH1 | P3 |
Not yet recruiting |
Endometrial Cancer |
2029-01-08 |
|
| 2018-013-00CH3 | P2 |
Recruiting |
Endometrial Cancer |
2025-12-01 |
57% |
| HMPL-013-N1-CRC104 | P2 |
Recruiting |
Colorectal Cancer |
2024-12-01 |
|
| 2022-013-00CH1 | P3 |
Recruiting |
Renal Cell Carcinoma |
2024-11-01 |
35% |